Combined Telomerase Inhibition and Immunotherapy in the Prevention and Treatment of Mammary Carcinomas
Abstract
The MMT mice develop multiple mammary carcinomas between the ages of 65-108 days with 100% penetrance. The mammary carcinomas occur in multiple stages. In addition, the progressive malignant transformation is closely correlated with telomerase activity using telomeric repeat amplification protocol (TRAP), suggesting that telomerase may be involved in the development of mammary carcinomas. Furthermore, constitutive deletion of the RNA component of telomerase significantly delayed the appearance of tumor and reduced the tumor burden. In the present project, we aim to assess the immunotherapy of MMT mice with deficiency of telomerase. Vaccination of telomerase heterozygotes MMT mice (GO) and first generation of mTERC4-MMT mice with fusions of dendritic cells and tumor cells (FC/MUC1) induced CTL activity comparable to that from MMT mice. In addition, the latent time required for tumor development was slight prolonged. Taken together, these results, although preliminary, suggest the feasibility of immunotherapy in the background of telomerase deletion.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2007
- Accession Number
- ADA465840
Entities
People
- Jianlin Gong
Organizations
- Boston University